Eligibility criteria-51 characters
Inclusion Criteria:
Age >>18 years.
Left ventricular ejection fraction (LVEF) <<50% within 2 years prior to planned randomization (assessed [...] randomization.
a.
For patients in sinus rhythm: NT- proBNP >>300 pg/mL or BNP >>100 pg/mL.
b.
For patients in atrial fibrillation: NT-proBNP >>600 pg/mL or BNP >>200 pg/mL.
Subjects with stable CHF (NYHA II/III functional [...] t 2 weeks (with the exception of diuretics).
Serum ferritin <<100 ng/mL or serum ferritin 100-300 ng/mL and TSAT ><20%.
Able and willing to perform a CPET at the time of rando [...] to provide informed consent.
Exclusion [...]
Secondary endpoints13 entries, revised
Change in VO2 at ventilatory threshold (ml/min）
Change in heart rate at peak exercise (bpm)
Change in 6-minute walking distance (m)
Change in concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP, pg/mL)
Change in left ventricular systolicejection functionfraction (LVEF, %)
Change in left ventricular global longitudinal stress (LVGLS, %)
Primary endpoints1 entry, revised
Change in peak VO2 (ml/min/kg）
Study description-21 characters
[...] HF, FAIR-HF) withheld intravenous iron in cases of ferritin >>800 ng/mL, hemoglobin >>16.0 g/dL, or transferrin saturation (TSAT) >>50%, while other studies (HEART-FID, IRONMAN) focused on tar [...] on dosing will repeat as long as the serum ferritin was not >>700ng/mL, or if TSAT was not >>40%.
Patients in the low dose group will receive repeat iron dosing if ferritin <<100 ng/mL, or if ferritin 100-300 ng/mL and TSAT <<20%, in line with criteria for iron deficiency in current guidelines.
Study sitescontacts updated at 1 of 1 site
Study titlerevised
The Effects of Low-Dose Versus High-Dose Intravenous IRON Therapy withWith Ferric DerisomaltoseDerisomaltOSE in Patients withWith Chronic Heart Failure and Iron Deficiency